Abstract
As gene therapy has matured from clinical trials to the first commercial products, understanding of the mechanisms of gene delivery has increased tremendously. This has also been reflected in viral vector development, creating a number of new approaches to tackle issues in transduction efficiency, biodistribution and viral safety. This review will highlight the most important issues and advancements in vector development, administration, surface modification, integration to host genome and safety. The gene therapy products currently available or near market approval, based on p53 expression (Gendicine™ and Advexin™), conditionally replicative adenoviruses (Oncorine™) and thymidine kinase + ganciclovir therapy (Cerepro®), are introduced with emphasis on the molecular mechanisms of action.
Keywords: Adenovirus, p53, conditional replication, thymidine kinase
Current Molecular Pharmacology
Title: Gene Therapy: The First Approved Gene-Based Medicines, Molecular Mechanisms and Clinical Indications
Volume: 1
Author(s): J. K. Raty, J. T. Pikkarainen, T. Wirth and S. Yla-Herttuala
Affiliation:
Keywords: Adenovirus, p53, conditional replication, thymidine kinase
Abstract: As gene therapy has matured from clinical trials to the first commercial products, understanding of the mechanisms of gene delivery has increased tremendously. This has also been reflected in viral vector development, creating a number of new approaches to tackle issues in transduction efficiency, biodistribution and viral safety. This review will highlight the most important issues and advancements in vector development, administration, surface modification, integration to host genome and safety. The gene therapy products currently available or near market approval, based on p53 expression (Gendicine™ and Advexin™), conditionally replicative adenoviruses (Oncorine™) and thymidine kinase + ganciclovir therapy (Cerepro®), are introduced with emphasis on the molecular mechanisms of action.
Export Options
About this article
Cite this article as:
Raty K. J., Pikkarainen T. J., Wirth T. and Yla-Herttuala S., Gene Therapy: The First Approved Gene-Based Medicines, Molecular Mechanisms and Clinical Indications, Current Molecular Pharmacology 2008; 1 (1) . https://dx.doi.org/10.2174/1874467210801010013
DOI https://dx.doi.org/10.2174/1874467210801010013 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Rock1 & 2 Perform Overlapping and Unique Roles in Angiogenesis and Angiosarcoma Tumor Progression
Current Molecular Medicine Jaridonin, a Novel Ent-Kaurene Diterpenoid from Isodon rubescens, Inducing Apoptosis via Production of Reactive Oxygen Species in Esophageal Cancer Cells
Current Cancer Drug Targets Natural Small Molecules as Stabilizers and Activators of Cancer-Associated NQO1 Polymorphisms
Current Drug Targets Innovative Cancer Treatments that Augment Radiotherapy or Chemotherapy by the Use of Immunotherapy or Gene Therapy
Recent Patents on Anti-Cancer Drug Discovery Drug Targeting Strategies for Photodynamic Therapy
Anti-Cancer Agents in Medicinal Chemistry Acute Lymphoblastic Leukemia and Regulatory T cells: Biomarkers and Immunopathogenesis
Current Immunology Reviews (Discontinued) Pathways Related to the Anti-Cancer Effects of Metabolites Derived from Cerrado Biome Native Plants: An Update and Bioinformatics Analysis on Oral Squamous Cell Carcinoma
Protein & Peptide Letters TC > 0.05 as a Pharmacokinetic Parameter of Paclitaxel for Therapeutic Efficacy and Toxicity in Cancer Patients
Recent Patents on Anti-Cancer Drug Discovery Mutant Cell Surface Receptors as Targets for Individualized Cancer Diagnosis and Therapy
Current Cancer Drug Targets ES-MDA: Enhanced Similarity-based MiRNA-Disease Association
Current Protein & Peptide Science Calreticulin is Differentially Expressed in Invasive Ductal Carcinoma: A Comparative Study
Current Proteomics Relevance of Drug Metabolizing Enzyme Activity Modulation by Tea Polyphenols in the Inhibition of Esophageal Tumorigenesis
Medicinal Chemistry Protease-Activated Receptors (PARs) as Therapeutic Targets: Development of Agonists / Antagonists and Modulation of Gastrointestinal Functions
Drug Design Reviews - Online (Discontinued) Nitric Oxide: State of the Art in Drug Design
Current Medicinal Chemistry Adrenoceptors: Non Conventional Target for Breast Cancer?
Current Medicinal Chemistry Analytical Techniques for DNA Methylation – An Overview
Current Pharmaceutical Analysis Microbial Interactions in Plants: Perspectives and Applications of Proteomics
Current Protein & Peptide Science Probiotic Multistrain Treatment May Eradicate Helicobacter pylori from the Stomach of Dyspeptics: A Placebo-Controlled Pilot Study
Inflammation & Allergy - Drug Targets (Discontinued) Integrins as Therapeutic Targets for Respiratory Diseases
Current Molecular Medicine Emerging Role of Circular RNAs in Kidney Diseases in Nephrology
Current Drug Targets